Brazilian food processing giant BRF has demonstrated remarkable resilience in the face of avian flu outbreaks and trade restrictions, posting strong Q2 2025 results that outperformed struggling competitors. The company’s ability to navigate global headwinds while maintaining profitability raises questions about its winning formula in turbulent times.
Financial Fortress Through Operational Excellence
At the heart of BRF’s success lies its disciplined cost-control measures. The BRF+ efficiency program generated savings of 208 million Brazilian reals in the quarter alone, contributing to an impressive international EBITDA margin of 17.3%—a standout performance in the current economic climate.
The company’s export strategy proved particularly effective, limiting poultry export declines to just 5% compared to the industry’s 15% contraction. Strategic market diversification helped offset potential revenue losses of up to 40% in key regions including the European Union and China.
Geographic Expansion Bears Fruit
BRF’s proactive approach to market development yielded significant results, with 11 new export approvals secured during the quarter. Notable additions to the company’s trade network include:
- Argentina
- Saudi Arabia
- Canada
The return of customers from Saudi Arabia and Chile validates BRF’s geographic expansion strategy. Domestically, the company strengthened its position with distribution reaching 330,000 retail outlets across Brazil.
Should investors sell immediately? Or is it worth buying BRF?
Solid Fundamentals Amid Uncertainty
Key financial metrics underscore BRF’s stability:
- Net revenue: 15.4 billion BRL (3% year-over-year growth)
- Quarterly EBITDA: 2.5 billion BRL
- Net income: 735 million BRL
The company achieved a record-low EBITDA leverage ratio of 0.54x, though its equity ratio of 1.5 remains higher than some industry peers.
Future-Proofing the Business
While meat products continue to drive core revenue, BRF is making strategic investments in plant-based proteins—a segment that grew 12.5% to 85 million BRL. The company has allocated 150 million BRL for alternative protein research, signaling long-term commitment to this emerging market.
Market response to the quarterly report has been positive, suggesting BRF’s combination of operational discipline and forward-looking strategy is resonating with investors. The challenge now lies in maintaining this trajectory amid ongoing market volatility.
Ad
BRF Stock: Buy or Sell?! New BRF Analysis from November 19 delivers the answer:
The latest BRF figures speak for themselves: Urgent action needed for BRF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 19.
BRF: Buy or sell? Read more here...
